With the incoming Trump Administration expected to revive international reference policy pricing policies, the biopharma industry wants ex-US government payers paying higher prices to help fund their “fair share” of global research and new drug development.
US vs. Foreign Drug Pricing Debate Must Include Global R&D ‘Free Riding,’ Pharma CEOs Say
Any Trump Administration policy involving international pricing should include foreign governments paying higher prices, as well as lowering US prices, CEOs say.
